Case report · 15 Jun 2023
Case reportPublished 2015
Ipilimumab Induced Encephalitis: A Case Report
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) is a helper T cell protein receptor that down regulates the immune system when bound to antigen presenting cells. Ipilimumab selectively binds to CTLA-4 inhibiting the immune tolerance to tumour cells and has recently been approved for the treatment of metastatic melanoma. Autoimmune sequelae are side-effects of such immunomodulatory therapies. We describe the first case of ipilimumab induced delayed onset encephalitis. Case: A 71 year-old man with BRAF wild-type metastatic melanoma received ipilimumab as first-line therapy. He presented with generalised weakness and headache following cycle 2 of ipilimumab. Blood analyses confirmed panhypopituitarism and MRI showed lymphocytic infiltration of pituitary gland, confirming autoimmune hypophysitis. Hormone replacement and a course of dexamethasone resolved the initial symptoms. Two months later he developed myoclonic jerks, drowsiness and mood elevation. CSF protein was raised with normal white and no malignant cells. Ipilimumab was stopped and high dose methylprednisolone was intiated resulting in improvement within 24hours. Post methylprednisolone electroencephalogram showed normal background activity with no seizures. Discussion: Gastrointestinal (colitis, nausea), skin (pruritis, rash) and fatigue are the most common (30-40%) ipilimumab induced side effects. Endocrinopathies are reported in 1-2% of patients. CTLA-4 is expressed by pituitary gland thereby being susceptible for lymphocytic hypophysitis following ipilimumab. Neurological side effects are even rarer yet (<1%). Autoimmune encephalitis can be a delayed response and in our case was around 2 months after second dose of ipilimumab therapy. No cases of delayed onset ipilimumab induced encephalitis have been described as yet, but with increasing use of immune therapies which up-regulate T cells, rarer immune sequelae are likely to be on the rise. Conclusion: Ipilimumab caused delayed onset autoimmune encephalitis and hypophysitis that was steroid responsive. Multi-specialty approach with early intervention of a neurologist and endocrinologist is a must for improved identification, treatment and outcomes.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Case report · 2018
Case Report: Treatment Resistant Ipilimumab Related Colitis in an Elderly Metastatic Melanoma Patient
Conference abstract · 27 Jul 2015
Advax-adjuvanted killed Japanese encephalitis virus (JEV) vaccine is safe in pregnant mares and in foals and induces robust immunological memory.
Case report · 27 Aug 2021
Combination Therapy with Nivolumab and Ipilimumab makes Asymptomatic Primary Biliary Cholangitis Symptomatic: A Case Report
Case report · 2015
A Case of Merkel Cell Carcinoma Treated with Anti-CTLA-4 Antibody (Ipilimumab)
More from this journal
The newest in Immunome Research.
Short communication · 29 Dec 2025
Beyond the Surface: Cellular Immune Responses in Uncharted Territories
Commentary · 27 Dec 2025
Stress-Induced Remodeling of Immune Cell Phenotypes
Perspective · 26 Dec 2025
Immune System Dysregulation in Complex Multisystem Disorders
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalImmunome Research
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Karen Boyd”
- BylineArticles whose byline prints “Dheeraj Kalladka”
- BylineArticles whose byline prints “James Overell”
- BylineArticles whose byline prints “Ashita Waterston”

